The four R-spondin secreted ligands (RSPO1–RSPO4) act via their cognate LGR4, LGR5 and LGR6 receptors to amplify WNT signalling1,2,3. Here we report an allelic series of recessive RSPO2 mutations in humans that cause tetra-amelia syndrome, which is characterized by lung aplasia and a total absence of the four limbs. Functional studies revealed impaired binding to the LGR4/5/6 receptors and the RNF43 and ZNRF3 transmembrane ligases, and reduced WNT potentiation, which correlated with allele severity. Unexpectedly, however, the triple and ubiquitous knockout of Lgr4, Lgr5 and Lgr6 in mice did not recapitulate the known Rspo2 or Rspo3 loss-of-function phenotypes. Moreover, endogenous depletion or addition of exogenous RSPO2 or RSPO3 in triple-knockout Lgr4/5/6 cells could still affect WNT responsiveness. Instead, we found that the concurrent deletion of rnf43 and znrf3 in Xenopus embryos was sufficient to trigger the outgrowth of supernumerary limbs. Our results establish that RSPO2, without the LGR4/5/6 receptors, serves as a direct antagonistic ligand to RNF43 and ZNRF3, which together constitute a master switch that governs limb specification. These findings have direct implications for regenerative medicine and WNT-associated cancers.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

  • 05 July 2018

    In this Letter, the surname of author Lena Vlaminck was misspelled ‘Vlaeminck’. This error has been corrected online.


  1. 1.

    de Lau, W. et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 476, 293–297 (2011).

  2. 2.

    Glinka, A. et al. LGR4 and LGR5 are R-spondin receptors mediating Wnt/β-catenin and Wnt/PCP signalling. EMBO Rep. 12, 1055–1061 (2011).

  3. 3.

    Carmon, K. S., Gong, X., Lin, Q., Thomas, A. & Liu, Q. R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/β-catenin signaling. Proc. Natl Acad. Sci. USA 108, 11452–11457 (2011).

  4. 4.

    Niswander, L. Pattern formation: old models out on a limb. Nat. Rev. Genet. 4, 133–143 (2003).

  5. 5.

    Niemann, S. et al. Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous family. Am. J. Hum. Genet. 74, 558–563 (2004).

  6. 6.

    Kazanskaya, O. et al. R-Spondin2 is a secreted activator of Wnt/β-catenin signaling and is required for Xenopus myogenesis. Dev. Cell 7, 525–534 (2004).

  7. 7.

    Kim, K. A. et al. R-Spondin proteins: a novel link to β-catenin activation. Cell Cycle 5, 23–26 (2006).

  8. 8.

    Nam, J. S., Turcotte, T. J., Smith, P. F., Choi, S. & Yoon, J. K. Mouse cristin/R-spondin family proteins are novel ligands for the Frizzled 8 and LRP6 receptors and activate β-catenin-dependent gene expression. J. Biol. Chem. 281, 13247–13257 (2006).

  9. 9.

    Ohkawara, B., Glinka, A. & Niehrs, C. Rspo3 binds syndecan 4 and induces Wnt/PCP signaling via clathrin-mediated endocytosis to promote morphogenesis. Dev. Cell 20, 303–314 (2011).

  10. 10.

    Zebisch, M. et al. Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist R-spondin. Nat. Commun. 4, 2787 (2013).

  11. 11.

    Bell, S. M. et al. R-spondin 2 is required for normal laryngeal-tracheal, lung and limb morphogenesis. Development 135, 1049–1058 (2008).

  12. 12.

    Aoki, M., Kiyonari, H., Nakamura, H. & Okamoto, H. R-spondin2 expression in the apical ectodermal ridge is essential for outgrowth and patterning in mouse limb development. Dev. Growth Differ. 50, 85–95 (2008).

  13. 13.

    Nam, J. S. et al. Mouse R-spondin2 is required for apical ectodermal ridge maintenance in the hindlimb. Dev. Biol. 311, 124–135 (2007).

  14. 14.

    Yamada, W. et al. Craniofacial malformation in R-spondin2 knockout mice. Biochem. Biophys. Res. Commun. 381, 453–458 (2009).

  15. 15.

    Brüchle, N. O. et al. RSPO4 is the major gene in autosomal-recessive anonychia and mutations cluster in the furin-like cysteine-rich domains of the Wnt signaling ligand R-spondin 4. J. Invest. Dermatol. 128, 791–796 (2008).

  16. 16.

    Başaran, S. et al. Tetra-amelia, lung hypo-/aplasia, cleft lip-palate, and heart defect: a new syndrome? Am. J. Med. Genet. 51, 77–80 (1994).

  17. 17.

    Sousa, S. B. et al. Tetra-amelia and lung hypo/aplasia syndrome: new case report and review. Am. J. Med. Genet. A. 146A, 2799–2803 (2008).

  18. 18.

    Xie, Y. et al. Interaction with both ZNRF3 and LGR4 is required for the signalling activity of R-spondin. EMBO Rep. 14, 1120–1126 (2013).

  19. 19.

    Proffitt, K. D. et al. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res. 73, 502–507 (2013).

  20. 20.

    Mazerbourg, S. et al. Leucine-rich repeat-containing, G protein-coupled receptor 4 null mice exhibit intrauterine growth retardation associated with embryonic and perinatal lethality. Mol. Endocrinol. 18, 2241–2254 (2004).

  21. 21.

    Morita, H. et al. Neonatal lethality of LGR5 null mice is associated with ankyloglossia and gastrointestinal distension. Mol. Cell. Biol. 24, 9736–9743 (2004).

  22. 22.

    Snippert, H. J. et al. Lgr6 marks stem cells in the hair follicle that generate all cell lineages of the skin. Science 327, 1385–1389 (2010).

  23. 23.

    Styrkarsdottir, U. et al. Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature 497, 517–520 (2013).

  24. 24.

    Sulem, P. et al. Identification of a large set of rare complete human knockouts. Nat. Genet. 47, 448–452 (2015).

  25. 25.

    Koizumi, M. et al. Lgr4 controls specialization of female gonads in mice. Biol. Reprod. 93, 90 (2015).

  26. 26.

    Jin, Y. R., Turcotte, T. J., Crocker, A. L., Han, X. H. & Yoon, J. K. The canonical Wnt signaling activator, R-spondin2, regulates craniofacial patterning and morphogenesis within the branchial arch through ectodermal-mesenchymal interaction. Dev. Biol. 352, 1–13 (2011).

  27. 27.

    Aoki, M. et al. R-spondin3 is required for mouse placental development. Dev. Biol. 301, 218–226 (2007).

  28. 28.

    van de Glind, G. C. et al. RNA-seq analysis of Lgr6+ stem cells and identification of an Lgr6 isoform. Exp. Dermatol. https://doi.org/10.1111/exd.13453 (2017).

  29. 29.

    Lebensohn, A. M. & Rohatgi, R. R-spondins can potentiate WNT signaling without LGRs. eLife 7, e33126 (2018).

  30. 30.

    Simon, A. & Tanaka, E. M. Limb regeneration. Wiley Interdiscip. Rev. Dev. Biol. 2, 291–300 (2013).

  31. 31.

    Hao, H. X. et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 485, 195–200 (2012).

  32. 32.

    Koo, B. K. et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488, 665–669 (2012).

  33. 33.

    Seshagiri, S. et al. Recurrent R-spondin fusions in colon cancer. Nature 488, 660–664 (2012).

  34. 34.

    Bond, C. E. et al. RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis. Oncotarget 7, 70589–70600 (2016).

  35. 35.

    Barker, N. et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608–611 (2009).

  36. 36.

    Wang, D. et al. Structural basis for R-spondin recognition by LGR4/5/6 receptors. Genes Dev. 27, 1339–1344 (2013).

  37. 37.

    Peng, W. C. et al. Structure of stem cell growth factor R-spondin 1 in complex with the ectodomain of its receptor LGR5. Cell Reports 3, 1885–1892 (2013).

  38. 38.

    Li, S. J. et al. Loss-of-function point mutations and two-furin domain derivatives provide insights about R-spondin2 structure and function. Cell. Signal. 21, 916–925 (2009).

  39. 39.

    Krug, U., Patzschke, R., Zebisch, M., Balbach, J. & Sträter, N. Contribution of the two domains of E. coli 5′-nucleotidase to substrate specificity and catalysis. FEBS Lett. 587, 460–466 (2013).

  40. 40.

    Monsoro-Burq, A. H. A rapid protocol for whole-mount in situ hybridization on Xenopus embryos. CSH Protoc. 2007, pdb.prot4809 (2007).

  41. 41.

    Van Nieuwenhuysen, T. et al. TALEN-mediated apc mutation in Xenopus tropicalis phenocopies familial adenomatous polyposis. Oncoscience 2, 555–566 (2015).

  42. 42.

    Naert, T., Van Nieuwenhuysen, T. & Vleminckx, K. TALENs and CRISPR/Cas9 fuel genetically engineered clinically relevant Xenopus tropicalis tumor models. Genesis 55, https://doi.org/10.1002/dvg.23005 (2017).

  43. 43.

    Moreno-Mateos, M. A. et al. CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. Nat. Methods 12, 982–988 (2015).

  44. 44.

    Boel, A. et al. BATCH-GE: Batch analysis of Next-Generation Sequencing data for genome editing assessment. Sci. Rep. 6, 30330 (2016).

Download references


We are grateful to the families of affected fetuses whose cooperation made this study possible. We thank M. Krahn and D. Bertola for contributing more families with TETAMS for ongoing research. We thank C. Niehrs for the RSPO2-ΔC-AP-PCS2 + construct. We thank D. Virshup for HEK293T-STF cells. The TALEN plasmids were obtained from C. H. K. Cheng. We are grateful to our groups’ members for discussion and advice. E.S.-R. thanks M. Ravi for her patience and support, and is supported by a BMRC Young Investigator Grant (1613851035). S.S.N. is a recipient of Senior Research Fellowship from Indian Council of Medical Research (45/10/2015-HUM-BMS). N.B. is funded by A*STAR and an NRF Investigatorship. B.R. is a fellow of the Branco Weiss Foundation, an A*STAR Investigator, a NRF and AAA fellow and a Young EMBO Investigator. This work was partly funded by the Department of Science and Technology, India, for the project ‘Application of autozygosity mapping and exome sequencing to identify genetic basis of disorders of skeletal development’ (SB/SO/HS/005/2014); by the Research Foundation, Flanders (FWO-Vlaanderen) (grants G0A1515N and G029413N), the Concerted Research Actions from Ghent University (BOF15/GOA/01) and the Hercules Foundation, Flanders (grant AUGE/11/14), Belgium; by TUBITAK 108S412 and 112S398 (ERA-Net consortiums, CRANIRARE and CRANIRARE2), Turkey; and by a Strategic Positioning Fund on Genetic Orphan Diseases from A*STAR, Singapore.

Reviewer information

Nature thanks C. Niehrs, C. Tabin and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Author information

Author notes

    • Lena Vlaminck

    Present address: Department of Plant Biotechnology and Bioinformatics, Ghent University, Ghent, Belgium

  1. These authors contributed equally: Emmanuelle Szenker-Ravi, Umut Altunoglu, Marc Leushacke.


  1. Institute of Medical Biology, A*STAR, Singapore, Singapore

    • Emmanuelle Szenker-Ravi
    • , Marc Leushacke
    • , Célia Bosso-Lefèvre
    • , Muznah Khatoo
    • , Amin Hajamohideen
    • , Thong Teck Tan
    • , Nick Barker
    •  & Bruno Reversade
  2. Medical Genetics Department, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

    • Umut Altunoglu
    • , Birsen Karaman
    • , Seher Başaran
    • , Zehra Oya Uyguner
    •  & Hülya Kayserili
  3. Department of Paediatrics, National University of Singapore, Singapore, Singapore

    • Célia Bosso-Lefèvre
    •  & Bruno Reversade
  4. Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium

    • Hong Thi Tran
    • , Thomas Naert
    • , Rivka Noelanders
    • , Lena Vlaminck
    •  & Kris Vleminckx
  5. CHU Nantes, Service de Génétique Médicale, Nantes, France

    • Claire Beneteau
    • , Xenia Latypova
    •  & Cédric Le Caignec
  6. Medical Genetics Unit, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

    • Sergio B. de Sousa
  7. University Clinic of Genetics, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

    • Sergio B. de Sousa
  8. Medical Genetics Department, Koç University School of Medicine (KUSOM), Istanbul, Turkey

    • Esra Börklü Yücel
    • , Hülya Kayserili
    •  & Bruno Reversade
  9. Department of Medical Genetics, Kasturba Medical College, Manipal University, Manipal, India

    • Shalini S. Nayak
    • , Anju Shukla
    •  & Katta Mohan Girisha
  10. INSERM, UMR1238, Bone Sarcoma and Remodeling of Calcified Tissue, Université Bretagne Loire, Nantes, France

    • Cédric Le Caignec
  11. Institute of Molecular Biology (IMB) gGmbH, Mainz, Germany

    • Natalia Soshnikova
  12. Cancer Research Institute, Kanazawa University, Kakuma-machi, Kanazawa, Japan

    • Nick Barker
  13. Centre for Regenerative Medicine, The University of Edinburgh, Edinburgh, UK

    • Nick Barker
  14. Institute of Molecular and Cellular Biology, A*STAR, Singapore, Singapore

    • Bruno Reversade
  15. Reproductive Biology Laboratory, Academic Medical Center (AMC), Amsterdam-Zuidoost, The Netherlands

    • Bruno Reversade
  16. Center for Medical Genetics, Ghent University, Ghent, Belgium

    • Kris Vleminckx


  1. Search for Emmanuelle Szenker-Ravi in:

  2. Search for Umut Altunoglu in:

  3. Search for Marc Leushacke in:

  4. Search for Célia Bosso-Lefèvre in:

  5. Search for Muznah Khatoo in:

  6. Search for Hong Thi Tran in:

  7. Search for Thomas Naert in:

  8. Search for Rivka Noelanders in:

  9. Search for Amin Hajamohideen in:

  10. Search for Claire Beneteau in:

  11. Search for Sergio B. de Sousa in:

  12. Search for Birsen Karaman in:

  13. Search for Xenia Latypova in:

  14. Search for Seher Başaran in:

  15. Search for Esra Börklü Yücel in:

  16. Search for Thong Teck Tan in:

  17. Search for Lena Vlaminck in:

  18. Search for Shalini S. Nayak in:

  19. Search for Anju Shukla in:

  20. Search for Katta Mohan Girisha in:

  21. Search for Cédric Le Caignec in:

  22. Search for Natalia Soshnikova in:

  23. Search for Zehra Oya Uyguner in:

  24. Search for Kris Vleminckx in:

  25. Search for Nick Barker in:

  26. Search for Hülya Kayserili in:

  27. Search for Bruno Reversade in:


The recruitment of families 1 and 2 and the initial discovery of RSPO2 mutations were made by the team of H.K. with the help of U.A. and Z.O.U. Further patient data and samples were collected by H.K. from S.B.d.S., S.S.N., A.S. and K.M.G., who provided TETAMS families 3 and 5. C.B., X.L. and C.L.C. independently identified a RSPO2 mutation in family 4. E.S.-R., M.L., K.V., N.S. and B.R. designed functional studies. N.B. provided single Lgr4, Lgr5 and Lgr6 knock-in mouse lines. E.S.-R., U.A., C.B., B.K., X.L., S.B., E.B.Y., C.L.C. and Z.O.U. performed whole-exome sequencing, chromosomal array analysis and sequencing analysis. E.S.-R., M.L., C.B.-L., M.K., H.T.T., T.N., R.N., A.H., N.S., T.T.T. and L.V. performed functional experiments. C.B.-L., M.K. and H.T.T. contributed equally to this work. E.S.-R., U.A., M.L., K.V., H.K. and B.R. wrote and revised the manuscript.

Competing interests

The authors declare no competing interests.

Corresponding authors

Correspondence to Kris Vleminckx or Nick Barker or Hülya Kayserili or Bruno Reversade.

Extended data figures and tables

  1. Extended Data Fig. 1 Pictures of affected fetuses, exome sequencing analysis in family 1 and genotyping analysis in family 3.

    a, Pictures and radiographs of indicated fetal cases illustrating severe limb defects in fetuses with HFH-RTRD, and the complete absence of limbs in fetuses with TETAMS. b, Summary of exome sequencing analysis for family 1, revealing a single biallelic missense mutation in the RSPO2 gene. c, Summary of genotyping in family 3 by SNP-array and array-CGH analysis, revealing a homozygous deletion including exon 6 of RSPO2.

  2. Extended Data Fig. 2 The RSPO2(R69C) and RSPO2(Q70X) mutants fail to bind ZNRF3.

    a, The RSPO2 R69 residue (highlighted in purple) is highly conserved in vertebrates and within the human paralogues RSPO1–RSPO4. Conserved cysteine residues of the Furin-like 1 domain are highlighted in pink. Protein alignment performed with ClustalO. b, Western blotting of protein extracts and supernatants from HEK293T cells transfected with indicated constructs. Deletion of the RSPO2 C-terminal domain (RSPO2-ΔC) decreases its retention on the cell surface without affecting its receptor binding and WNT enhancement properties38. The RSPO2(R69C) mutant was almost undetectable in conditioned media but was greatly increased by the addition of heparin in the medium. c, Co-immunoprecipitation of wild-type and mutant forms of RSPO2-ΔC-AP with the ProteinG-Flag beads only. Asterisk indicates an unspecific band. d, Co-immunoprecipitation of wild-type and mutant forms of RSPO2-ΔC-AP with the ZNRF3-ECD-Flag E3 ligase. Asterisk indicates an unspecific band. e, Cell-surface binding assay of HEK293T cells transfected with empty vector, LGR5 or RNF43, using equivalent amounts of RSPO2-ΔC-AP conditioned media (western blot). Experiments in be were repeated three times. f, SUPERTOPFLASH assay in HEK293T-STF cells transfected with WNT3A in the presence of equivalent amounts of RSPO2-ΔC-AP conditioned media (western blot). n = 4 biological replicates. Data are mean ± s.e.m. NS, not significant. **P < 0.01, one-way ANOVA test with Bonferroni’s correction. For gel source data, see Supplementary Fig. 1Source Data.

  3. Extended Data Fig. 3 Mouse Lgr4/5/6 knock-in embryos do not recapitulate the Rspo2 and Rspo3 phenotypes.

    a, Table indicating the proportion and numbers of analysed embryos. The different genotypes were obtained in Mendelian ratio (P > 0.05, χ2 test). b, Normal limbs of embryos with indicated genotypes including a Lgr4/5/6 triple-knockout embryo. All obtained embryos (see a) had a similiar phenotype. FL, forelimbs; HL, hindlimbs; L, left; R, right. Scale bar, 1 mm. c, Normal lungs of embryos with indicated genotypes including a Lgr4/5/6 triple-knockout embryo. Comparable lung length relative to body length is indicated. Scale bar, 1 mm. All obtained embryos (see a) had a similiar phenotype. d, H&E staining of coronal sections of the heads through the oral cavity. Scale bar, 1 mm. Close-ups of the palatal shelves illustrate the cleft palate present in the Lgr5/6 double-knockout (n = 2) and Lgr4/5/6 triple-knockout (n = 2) embryos (indicated by black arrow heads). e, Properly vascularized placenta of a Lgr4/5/6 triple-knockout embryo compared to a Lgr6-knockout embryo. All obtained embryos (see a) had a similiar phenotype. Scale bar, 1 mm.Source Data.

  4. Extended Data Fig. 4 Mouse Lgr4, Lgr5 and Lgr6 knock-in embryos recapitulate the knockout phenotypes.

    a, Illustration of the GFP knock-in in exon 1 of the Lgr4, Lgr5 and Lgr6 genes, which cause loss-of-function mutations. b, Liver weight in single Lgr4−/− (n = 2) and triple Lgr4/5/6−/− (n = 2) compared to wild-type (n = 3) E14.5 embryos. Data are mean ± s.e.m. NS, not significant. *P < 0.05, one-way ANOVA test with Bonferroni’s correction. c, Lgr4−/− embryos (n = 4) have a smaller liver. Liver weight is indicated. Scale bar, 1 mm. d, Lgr4−/− embryos (n = 2) show female-to-male sex reversal. Blue arrowheads point to male-specific coelomic vessels. Genetic genders (XY or XX) are indicated. Scale bar, 0.1 mm. e, H&E staining of coronal sections of the heads through the oral cavity. Scale bar, 1 mm. Close-ups of the tongue illustrate the ankyloglossia phenotype (tongue attached to the mouth floor, black arrow heads) in Lgr5−/− embryos (n = 4), whereas the tongue is detached for other genotypes (white arrowheads).Source Data.

  5. Extended Data Fig. 5 Mouse Lgr4, Lgr5 and Lgr6 knock-in cause loss-of-function mutations.

    a, b, qPCR analyses for Lgr4, Lgr5 and Lgr6 expression in E14.5 limbs (a) and lungs (b) of wild-type, heterozygous and homozygous mutant embryos for the respective genes. c, d, qPCR analyses for Lgr4 and Lgr5 in embryonic intestine (c) and embryonic liver (d) of embryos with indicated genotype. e, qPCR analyses for Lgr6 in embryonic and adult skin of wild-type versus homozygous animals. n indicates number of embryos. Data are mean ± s.e.m. NS, not significant. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA test with Bonferroni’s correction or two-tailed unpaired t-test with Welch’s correction when less than three groups were compared (for Lgr6 qPCR analysis). f, Duplex RNAscope for the indicated gene (blue) and Rspo2 (pink) in transverse sections of wild-type E14.5 lungs. Strongly expressed genes are denoted in bold (summary on the right). Scale bars, 0.2 mm. Experiment repeated with three different wild-type embryos.Source Data.

  6. Extended Data Fig. 6 Expression analyses in cells derived from mutant embryos.

    a, qPCR analyses for Lgr4, Lgr5 and Lgr6 in NPCs derived from embryos of indicated genotypes. n = 4 biological replicates. b, qPCR analyses for Lgr4 and Lgr6 in iPS cells derived from NPCs of indicated genotypes. n = 3 biological replicates. c, qPCR analyses for Lgr4 and Lgr5 in SV40-immortalized dermal fibroblasts derived from embryos of indicated genotypes. n = 3 biological replicates. d, qPCR analyses for Rspo2, Rspo3 and Znrf3 in Lgr4/5/6 triple-knockout SV40-immortalized fibroblasts, transfected with indicated siRNAs. n = 3 biological replicates. Data are mean ± s.e.m. NS, not significant. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA test with Bonferroni’s correction.

  7. Extended Data Fig. 7 Extreme phenotypes of Xenopus tropicalis mutant tadpoles.

    a, Control and rspo2 CRISPR–Cas9-injected tadpole showing a complete tetra-amelia phenotype probably due to incomplete cleavage at the time of injection and leakage of the CRISPR–Cas9 between the two blastomeres (n = 3 froglets). Scale bar, 1 cm. b, Alizarin red and alcian blue staining of a double-mutant rnf43/znrf3 TALEN-injected tadpole showing complete mirror-image diplopodia of both hindlimbs with 10 digits each (n = 4 froglets). Scale bar, 0.2 cm.

  8. Extended Data Table 1 Clinical characteristics of affected individuals with biallelic RSPO2 mutations
  9. Extended Data Table 2 List of primers

Supplementary information

  1. Supplementary Figure 1

    This file contains gel source data for immunoblots presented in the main and extended data figures including molecular weight markers (kDa).

  2. Reporting Summary

  3. Supplementary Table 1 (Related to Fig. 4)

    This file contains an overview of the cutting efficiencies of the CRISPR gRNAs and TALENs as determined by PCR amplification and sequencing (MiSeq) of the targeted regions

Source data

About this article

Publication history




Issue Date



Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.